Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3065 |
|
Actual shortage: | 231 (8%) | |
Anticipated shortage: | 16 (1%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2809 (92%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
30 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-ENALAPRIL | 5MG | TABLET | Resolved | 2017-11-01 | 2017-12-20 | 27710 |
APO-ENALAPRIL | 5MG | TABLET | Resolved | 2018-02-01 | 2018-04-07 | 37953 |
APO-ENALAPRIL | 5MG | TABLET | Resolved | 2018-10-25 | 2018-12-08 | 65595 |
APO-ENALAPRIL | 5MG | TABLET | Resolved | 2019-09-18 | 2019-12-19 | 94168 |
APO-ENALAPRIL | 5MG | TABLET | Resolved | 2020-09-09 | 2021-03-09 | 123932 |
APO-ENTECAVIR | 0.5MG | TABLET | Resolved | 2017-03-10 | 2017-10-11 | 311 |
APO-ENTECAVIR | 0.5MG | TABLET | Resolved | 2018-09-04 | 2019-05-13 | 59813 |
APO-ENTECAVIR | 0.5MG | TABLET | Resolved | 2020-03-27 | 2020-07-06 | 109678 |
APO-ENTECAVIR | 0.5MG | TABLET | Resolved | 2023-05-19 | 2023-06-16 | 192815 |
APO-ERLOTINIB | 100MG | TABLET | Resolved | 2019-02-06 | 2019-11-21 | 74875 |
APO-ERLOTINIB | 150MG | TABLET | Resolved | 2019-02-06 | 2019-11-21 | 74878 |
APO-ERLOTINIB | 25MG | TABLET | Resolved | 2019-02-06 | 2019-11-21 | 74881 |
APO-ESCITALOPRAM | 10MG | TABLET | Resolved | 2017-03-13 | 2017-03-29 | 742 |
APO-ESCITALOPRAM | 20MG | TABLET | Resolved | 2017-03-13 | 2017-04-20 | 745 |
APO-ESCITALOPRAM | 20MG | TABLET | Resolved | 2018-11-30 | 2019-02-08 | 68218 |
APO-ESCITALOPRAM | 20MG | TABLET | Resolved | 2018-12-12 | 2019-02-26 | 69299 |
APO-ESCITALOPRAM | 10MG | TABLET | Resolved | 2019-03-05 | 2019-03-09 | 77878 |
APO-ESCITALOPRAM | 20MG | TABLET | Resolved | 2019-03-05 | 2019-03-09 | 77881 |
APO-ESCITALOPRAM | 10MG | TABLET | Resolved | 2019-03-06 | 2019-03-09 | 77971 |
APO-ESCITALOPRAM | 10MG | TABLET | Resolved | 2019-06-26 | 2020-01-20 | 87517 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |